This Coronavirus Stock Just Got More Attractive: Should You Buy?

Few stocks have performed better than Vaxart (NASDAQ: VXRT) of late. Year to date, shares of this company are up by more than 3,400%. And despite these massive gains, Vaxart's market cap is still just $1.34 billion, a reasonable level for a clinical-stage biotech.

Vaxart's efforts to develop an oral vaccine for the novel coronavirus have been instrumental to its performance in the market this year. However, investors will want to pay attention to another opportunity the company is facing, as well.

Source Fool.com